Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms
CXB or DMC combination with canonical chemotherapy may be a promising chemotherapy strategy against cervical cancer growth, because it can selectively block multiple cell processes including inhibition of energy pathways and in consequence ATP-dependent processes such as cell proliferation, glycoprotein-P activity, ROS production and mitophagy, with no apparent effects on non-cancer cells.
Authors
- Rebeca López‐Marure (ORCID: https://orcid.org/0000-0003-1090-5084)
- Sara Rodríguez‐Enríquez (ORCID: https://orcid.org/0000-0002-0822-1233)
- Rafael Moreno‐Sánchez (ORCID: https://orcid.org/0000-0002-9587-7184)
- Silvia Cecilia Pacheco-Velázquez (ORCID: https://orcid.org/0000-0002-6772-6389)
- Tuuli Käämbre (ORCID: https://orcid.org/0000-0001-5755-4694)
- Joaquín Alberto Padilla-Flores
- Israel Pérez-Torres (ORCID: https://orcid.org/0000-0001-6510-2954)
- Jorge Luis Vargas-Navarro
- Diana Xochiquetzal Robledo‐Cadena (ORCID: https://orcid.org/0000-0002-7287-938X)
Institutions
- Universidad Autónoma de Tlaxcala (MX)
- Oregon Health & Science University (US)
- National Institute of Chemical Physics and Biophysics (EE)
- Instituto Nacional de Cardiología (MX)
- Universidad Nacional Autónoma de México (MX)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1371/journal.pone.0308233
- Citations
- 3
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 1.34
Funders
- Keemilise ja Bioloogilise Füüsika Instituut
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México